[Novel therapeutic approach to bone metabolic disorders using RANKL vaccination].
Juji
Takuo
T
Section of Orthopaedics, Sagamihara National Hospital.
Tanaka
Sakae
S
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D015519:Bone Density; D001862:Bone Resorption / Q000517:prevention & control; D004195:Disease Models, Animal; D006023:Glycoproteins / Q000276:immunology* / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000276:immunology* / Q000502:physiology / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor; D014612:Vaccines / Q000627:therapeutic use*
D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; D014612:Vaccines